Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1705 | Coronarin D methyl ether |
| 1. Coronarin D methyl ether has inhibitory effects on the increase in vascular permeability, nitric oxide production, and inducible nitric oxide synthase induction. | |
| BCN1708 | Catalpalactone |
| 1. Catalpalactone can inhibit dopamine biosynthesis by reducing tyrosine hydroxylase (TH) and aromatic-l-amino acid decarboxylase (AADC) activities and enhance L-DOPA- induced cytotoxiciy in PC12 cells. 2. Catalpalactone displays good cytotoxicity activities against two human tumor cell lines(MCF-7,BxPC3). 3. Catalpalactone exhibits significant inhibitory activity against 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced Epstein-Barr virus early antigen (EBV-EA) activation in Raji cells. 4. Catapalactone exhibits potent inhibitory effects on lipopolysaccharide-induced NO synthesis in RAW 264.7 cells , with IC50 values of 9.80 microM. 5. Catalpalactone exhibits high antitermitic activity. | |
| BCN1710 | 3',5,5',7-Tetrahydroxyflavanone |
| 1. 5,7,3',5'-Tetrahydroxyflavanone has inhibitory effects on HIV-1 reverse transcriptase (RT)-associated RNase H function, it may have antiviral activity against HIV-1. 2. 5,7,3',5'-Tetrahydroxyflavanone has anti-inflammatory properties, it can inhibit nitric oxide (NO) production with IC50 values of 18.5 uM, the inhibitory effect is accompanied by dose-dependent decreases in LPS-induced nitric oxide synthase (iNOS) in RAW 264.7 cells. | |
| BCN1711 | Villosin |
| 1. Villosin shows inhibitory effects against nitric oxide production in LPS and IFN-γ-induced RAW 264.7 murine macrophages with IC50 values of 5.99 ± 1.20 ug/ml. 2. Villosin exhibits potent cytotoxic activity , it may be used as a potential lead molecule for antitumor therapeutic development. | |
| BCN1717 | Lupenone |
| Lupenone and lupeol inhibit protein tyrosine phosphatase 1B (PTP1B) with IC50 values of 13.7 ± 2.1 and 5.6 ± 0.9 uM, respectively, they are non−competitive inhibitors of PTP1B, and PTP1B appears to be an attractive target for the development of new drugs for type 2 diabetes and obesity. Lupenone stimulates melanogenesis by increasing the tyrosinase enzyme expression via mitogen-activated protein kinase phosphorylated extracellular signal-regulated kinases 1 and 2 phosphorylation inhibition. A 1 : 4 mixture of Lupenone and caryophyllene oxide shows trypanocidal activity. | |
